See the Glossary for more terms.
NIAID's divisions are particularly interested in applications that address the areas listed below. Also read NIAID's section of the NIH Omnibus Solicitation for SBIR and STTR Grant Applications.
Note that NIAID does not support clinical trials through the SBIR or STTR programs, with the exception of our NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44). For details, read "Can my small business obtain funding for a clinical trial?"
Scroll or click down to DAIDS, DAIT, or DMID.
Division of AIDS—Small Business High-Priority Areas of Interest
Updated March 28, 2013.
Development of formulation strategies to deliver antiretrovirals to specific target cells or tissues. Development of sustained release formulations to be delivered by oral, injectable, implantable, or transdermal routes of administration for treatment of HIV infection.
Development of rapid tests for the detection of ARTs in various human matrices (e.g. blood, urine, hair). The assay should require minimal operator effort and expertise, and include the development, incorporation, and validation of process controls.
Division of Allergy, Immunology, and Transplantation—Small Business High-Priority Areas of Interest
Updated February 28, 2013.
Development of medical countermeasures to protect against, mitigate, and treat the short- and long-term effects of radiation exposure due to terrorist attack.
Development of novel or improved decorporation agents to remove radionuclides from the body following accidental inhalation, ingestion or wound entry.
Identification of radiation exposure biomarkers and development of new biodosimetry methods and devices for triage of radiation-exposed people.
Novel approaches for detecting infants at risk for developing asthma and other allergic diseases.
Immune targets for asthma and allergic disease interventions. Development of immunotherapies to prevent or treat allergic diseases.
Single cell assays to isolate and study allergen-specific lymphocytes.
Development of new reagents and non-murine animal models for allergy research.
Innovative treatments for autoimmune diseases.
Biomarkers to measure risk, disease activity, and therapeutic response in autoimmune diseases.
High throughput assay of T-cell activity in autoimmune diseases.
Standardized validated diagnostic criteria and outcome measures for autoimmune diseases correlated with disease activity.
Biomarkers of host immune defense.
Single cell and other sample-sparing assays for study of human immunology.
Methods and analysis tools to facilitate high throughput, high resolution MHC typing in humans and non-human primates.
Immunomodulatory agents to prevent graft rejection and biomarkers to predict transplantation outcomes.
Division of Microbiology and Infectious Diseases—Small Business High-Priority Areas of Interest
Updated February 3, 2012.
Identify and qualify infectious disease-related biomarkers, including:
Development of more sensitive and accurate methods of direct detection of Borrelia burgdorferi for the purpose of diagnosing Lyme disease patients. Diagnostic approaches that contain one or more of the following are also encouraged: substantial and significant advances over conventional antibody-based approaches, methods that take into account host response, ability to detect and differentiate multiple strains of Borrelia burgdorferi, and discriminate between active and previous infection.
Vaccines for NIAID Category A, B, and C priority pathogens including influenza, Ebola, Marburg, arenavirus, and other viral encephalitides.
Vaccine development for tuberculosis, STIs, hepatitis B and C, and malaria and other high-impact global parasitic diseases.
Vaccine enhancement and formulation technologies with the goal of providing protection against multiple infectious disease agents, providing accelerated immune responses (more rapid schedules or reduced number of immunizations), increase ease of administration (i.e., self-administration), and increase product stability to minimize cold chain requirements.
Therapeutics for NIAID Category A, B, and C priority pathogens including smallpox, viral hemorrhagic fevers, viral encephalitides, botulinum neurotoxins, and influenza.
Therapeutics for tuberculosis, hepatitis B and C, and malaria and other high-impact global parasitic diseases.
Therapeutics exhibiting broad-spectrum activity against microbial pathogens.
Therapeutic enhancement and formulation technologies with the goal of improving drug development timeframes, productivity, efficacy, specificity, safety, stability, and delivery.
Development of simple, rapid, field-deployable, sensitive, and specific point-of-care in vitro diagnostics for:
Development of next generation sequencing and genomic technologies for new diagnostic strategies for infectious diseases including molecular signatures developed from studies on human microbiome and pathogen-host interactions.
Last Updated July 26, 2013
Last Reviewed March 28, 2013